150 mg powder for solution for infusion
It is indicated for prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p><strong>Fosaprepitant powder for solution for infusion</strong> is a sterile, lyophilized prodrug of aprepitant used as an antiemetic agent. It is manufactured under strict pharmaceutical standards to ensure high purity and stability for intravenous administration.</p>
<h3>Application</h3>
<ul>
<li><strong>Oncology Centers:</strong> Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adult patients receiving highly emetogenic regimens.</li>
<li><strong>Hospitals & Clinics:</strong> Administration during post-operative care protocols involving opioid-based anesthesia or other emetogenic procedures.</li>
</ul>
<h3>Precautions</h3>
<ul>
<li><strong>Safety:</strong> Requires aseptic handling to prevent contamination; store in controlled temperature environments away from direct light.</li>
<li><strong>Maintenance:</strong> Strictly adhere to expiration dates and inspect packaging integrity before reconstitution to ensure patient safety.</li>
</ul>